Neurological adverse events associated with immune checkpoint inhibitors: a pharmacovigilance study based on the FAERS and JADER databases
Neurologische unerwünschte Ereignisse unter Immun-Checkpoint-Inhibitoren: Pharmakovigilanzstudie auf Basis der FAERS- und JADER-Datenbanken
Frontiers in Pharmacology · 05.11.2026 · 17
DOI: 10.3389/fphar.2026.1928236 ↗Auf einen Blick
In FAERS und JADER wurden neurologische Meldungen unter 7 Immun-Checkpoint-Inhibitoren beschrieben. Es zeigten sich wiederkehrende neuromuskuläre und ZNS-Signale sowie unterschiedliche Zeit-bis-zum-Eintritt-Muster.
Fragestellung
Welche neurologischen unerwünschten Ereignisse werden unter 7 Immun-Checkpoint-Inhibitoren in FAERS und JADER gemeldet, und wie sind die Onset-Muster?
Methode
Pharmakovigilanzstudie mit Disproportionalitätsanalysen in FAERS und JADER; FAERS zusätzlich mit logistischer Regression und Zeit-bis-zum-Eintritt-Analysen.
Ergebnisse
3.915 NAE-Meldungen aus FAERS und 2.929 aus JADER. 111 positive Drug-PT-Paare in FAERS und 49 in JADER. Myasthenia gravis zeigte ein Signal für alle 7 bzw. 6 analysierten ICIs. In FAERS waren Alter ≥65 Jahre und Kombinationstherapie mit höherer Meldewahrscheinlichkeit verbunden.
Einschränkungen
JADER-Cemiplimab-Daten wurden nur deskriptiv dargestellt; die Autoren betonen deskriptiven, hypothesengenerierenden Charakter.
Schlussfolgerung der Autor:innen
Die neurologischen Meldungen unter ICIs zeigten wiederkehrende neuromuskuläre und zentrale Signale sowie teilweise Übereinstimmung zwischen FAERS und JADER. Die Befunde sind deskriptiv und erlauben keinen Vergleich der klinischen Sicherheit.
Kernaussagen
- 3.915 NAE-Meldungen in FAERS, 2.929 in JADER
- Myasthenia gravis mit Signal für alle untersuchten ICIs
- Onset-Muster je nach Wirkstoff und Datenbank unterschiedlich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.11.2026. Verfasst von Huilin Luo und 4 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangxi Zhuang Autonomous Region.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Neurological adverse events (NAEs) have been reported during immune checkpoint inhibitor (ICI) therapy, but their reporting spectrum and onset patterns across drugs and pharmacovigilance databases remain incompletely characterized.
Methods
We conducted a pharmacovigilance study of seven ICIs using the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) database. Primary drug–preferred term (PT) signals were evaluated using whole-database disproportionality analyses. An exploratory FAERS analysis compared PD-L1 with PD-1 inhibitors within study-defined tumor-indicator strata. Factors associated with NAE reporting were assessed in FAERS by univariate and multivariable logistic regression, and time-to-onset (TTO) was summarized using descriptive statistics and Weibull analyses. JADER cemiplimab data were summarized descriptively only because of sparse reporting.
Results
The analysis included 3,915 NAE reports from FAERS and 2,929 from JADER. The heatmaps displayed 111 positive drug–PT pairs across 31 PTs in FAERS and 49 across 16 PTs in JADER. Myasthenia gravis showed a disproportionality signal for all seven ICIs in non-Japanese FAERS reports and for all six ICIs included in the JADER signal analysis; encephalitis-related terms and immune-mediated myositis also recurred, although drug-specific patterns varied. In FAERS, complete-case regression included 111,879 ICI-related reports with 2,887 NAEs. Age ≥65 years and ICI combination therapy were associated with higher adjusted odds of NAE reporting, whereas PD-L1 and CTLA-4 monotherapy were associated with lower adjusted reporting odds relative to PD-1 monotherapy. The stratified comparison showed lower myasthenia gravis reporting odds for PD-L1 than PD-1 in both strata; encephalitis confidence intervals included 1. Drug-level median TTOs ranged from 16 to 43 days in FAERS and from 16 to 32 days in JADER, with heterogeneous Weibull patterns across drugs and databases.
Conclusion
ICI-associated neurological reports showed recurring neuromuscular and central nervous system signals, partial qualitative concordance between non-Japanese FAERS reports and JADER, and heterogeneous onset patterns across drugs. The observed reporting associations do not establish comparative clinical safety. Overall, these findings are descriptive and hypothesis-generating and warrant confirmation in studies with exposure denominators, clinically adjudicated diagnoses, and longitudinal follow-up.
Förderung
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
Zitieren
APA
Luo, H., Xie, X., Qin, S., Pan, L., & Ye, L. (2026). Neurological adverse events associated with immune checkpoint inhibitors: a pharmacovigilance study based on the FAERS and JADER databases. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1928236
Vancouver
Luo H, Xie X, Qin S, Pan L, Ye L. Neurological adverse events associated with immune checkpoint inhibitors: a pharmacovigilance study based on the FAERS and JADER databases. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1928236
BibTeX
@article{Luo2026,
author = {Luo, Huilin and Xie, Xianlong and Qin, Shiran and Pan, Linghui and Ye, Liu},
title = {Neurological adverse events associated with immune checkpoint inhibitors: a pharmacovigilance study based on the FAERS and JADER databases},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1928236}
}
EUVIMED